Advertisement

Topics

Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article

04:00 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, works with Enleofen Bio Pte Ltd (‘Enleofen Bio'), to de...

Other Sources for this Article

Abzena PLC
John Burt, CEO
+44 1223 903498
or
Campbell Bunce, SVP Scientific Operations
Min Park, Global Head of Marketing
+1 267 54 7752
or
Instinctif Partners (Abzena)
Melanie Toyne Sewell / Alex Shaw / Deborah Bell
+44 20 7457 2020
abzena@instinctif.com
or
Enleofen Bio Pte Ltd
Stuart Cook, Co-Founder
info@enleofen.com

NEXT ARTICLE

More From BioPortfolio on "Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...